We are live on
!
Find out more
OMERS Administration Corp Portfolio holdings
AUM
$16.7B
Turnover
31.48%
1-Year Est. Return
35.95%
This Fund
S&P 500
This Quarter
Est. Return
-2.21%
1 Year Est. Return
+35.95%
3 Year Est. Return
+106.41%
5 Year Est. Return
+114.67%
10 Year Est. Return
+344.51%
AUM
$15.6B
AUM Growth
+$1.52B
(+11%)
Cap. Flow
+$2.38B
Cap. Flow
% of AUM
15.32%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
1,205
New
175
Increased
591
Reduced
154
Closed
109
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$993M |
| 2 |
Brookfield Business Corp Class A Subordinate Voting Shares
BBUC
|
+$414M |
| 3 |
Coca-Cola
KO
|
+$242M |
| 4 |
AstraZeneca
AZN
|
+$159M |
| 5 |
Merck
MRK
|
+$153M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BBU
Brookfield Business Partners
BBU
|
+$424M |
| 2 |
Waste Connections
WCN
|
+$184M |
| 3 |
Broadcom
AVGO
|
+$153M |
| 4 |
Nike
NKE
|
+$150M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$145M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.77% |
| 2 | Financials | 16.4% |
| 3 | Industrials | 10.28% |
| 4 | Healthcare | 9.9% |
| 5 | Miscellaneous | 9.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1051
Range Capital Acquisition Corp II Warrants
RNGTW
| $66K | ﹤0.01% |
200,000
| – | – |
2025 Q4
1 quarter
|
|
1052
Oramed Pharmaceuticals
ORMP
$169M
| $62.6K | ﹤0.01% |
+18,400
| New | +$62.4K |
2026 Q1
0 quarters
|
|
1053
Minerva Neurosciences
NERV
$112M
| $62.1K | ﹤0.01% |
+10,300
| New | +$59.1K |
2026 Q1
0 quarters
|
|
1054
Orion Office REIT
ONL
$118M
| $58.5K | ﹤0.01% |
27,200
-31,200
| -53% | -$72.2K |
2025 Q4
1 quarter
|
|
1055
Pyrophyte Acquisition Corp II Warrants
PAII.WS
| $57.8K | ﹤0.01% |
175,000
| – | – |
2025 Q4
1 quarter
|
|
1056
Fractyl Health
GUTS
$20.6M
| $56.7K | ﹤0.01% |
10,325
-4,617
| -31% | -$51.1K |
2025 Q4
1 quarter
|
|
1057
Rani Therapeutics
RANI
$73.9M
| $56.2K | ﹤0.01% |
76,500
+7,300
| +11% | +$9.33K |
2025 Q4
1 quarter
|
|
1058
AN2 Therapeutics
ANTX
$128M
| $54K | ﹤0.01% |
+15,800
| New | +$32.6K |
2026 Q1
0 quarters
|
|
1059
Venu Holding Corp
VENU
$65.6M
| $51K | ﹤0.01% |
15,400
-12,800
| -45% | -$73.8K |
2025 Q4
1 quarter
|
|
1060
LightWave Acquisition Corp Warrants
LWACW
$1.1M
| $46.9K | ﹤0.01% |
187,500
| – | – |
2025 Q4
1 quarter
|
|
1061
Pioneer Acquisition I Corp Warrants
PACHW
$1.51M
| $46.2K | ﹤0.01% |
220,000
| – | – |
2025 Q4
1 quarter
|
|
1062
Oxley Bridge Acquisition Ltd Warrants
OBAWW
| $45.1K | ﹤0.01% |
220,000
| – | – |
2025 Q4
1 quarter
|
|
1063
Apyx Medical
APYX
$107M
| $44.3K | ﹤0.01% |
12,000
-19,722
| -62% | -$73.7K |
2025 Q4
1 quarter
|
|
1064
PepGen
PEPG
$180M
| $44.1K | ﹤0.01% |
24,900
-2,700
| -10% | -$15.2K |
2025 Q4
1 quarter
|
|
1065
Genelux
GNLX
$109M
| $42.6K | ﹤0.01% |
17,600
-37,200
| -68% | -$101K |
2025 Q4
1 quarter
|
|
1066
Dawson Geophysical
DWSN
$69.3M
| $40.5K | ﹤0.01% |
+11,700
| New | +$32.4K |
2026 Q1
0 quarters
|
|
1067
Whitehawk Therapeutics
WHWK
$165M
| $39.7K | ﹤0.01% |
+11,500
| New | +$36K |
2026 Q1
0 quarters
|
|
1068
NMP Acquisition Corp Right
NMPAR
| $39.1K | ﹤0.01% |
200,000
| – | – |
2025 Q4
1 quarter
|
|
1069
Rapid Micro Biosystems
RPID
$38.3M
| $36.1K | ﹤0.01% |
15,900
-8,500
| -35% | -$31.1K |
2025 Q4
1 quarter
|
|
1070
Abundia Global Impact Group
AGIG
$36.6M
| $35.3K | ﹤0.01% |
+24,500
| New | +$63.8K |
2026 Q1
0 quarters
|
|
1071
Insight Molecular Diagnostics
IMDX
$98.5M
| $34.4K | ﹤0.01% |
10,500
-15,664
| -60% | -$90.9K |
2025 Q4
1 quarter
|
|
1072
FIGX Capital Acquisition Corp Warrant
FIGXW
$905K
| $33.4K | ﹤0.01% |
131,000
| – | – |
2025 Q4
1 quarter
|
|
1073
McKinley Acquisition Corp Rights
MKLYR
| $33K | ﹤0.01% |
300,000
| – | – |
2025 Q4
1 quarter
|
|
1074
Galata Acquisition Corp II Warrant
LATAW
| $30K | ﹤0.01% |
100,000
| – | – |
2025 Q4
1 quarter
|
|
|
EMISR
1075
Emmis Acquisition Corp Rights
EMISR
| $27.7K | ﹤0.01% |
198,021
| – | – |
2025 Q4
1 quarter
|
|
Similar funds
NMO
OMERS Administration Corp's Q1 2026 Portfolio in Review
As of Q1 2026, OMERS Administration Corp held 1,205 positions worth $15.6B, up 11% from $14B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
OMERS Administration Corp deployed $2.38B of net new capital in Q1 2026, opening 175 new positions and adding to 591 existing holdings. Its largest new stake was Vanguard S&P 500 ETF: 1,587,839 shares worth $949M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 26% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Waste Connections, an estimated $184M trimmed.
- OMERS Administration Corp's largest Q1 2026 buy was Vanguard S&P 500 ETF: 1,587,839 shares worth $949M.
- OMERS Administration Corp added most to Brookfield Business Corp Class A Subordinate Voting Shares in Q1 2026, an estimated $414M increase.
- OMERS Administration Corp's biggest Q1 2026 reduction was Waste Connections, cutting an estimated $184M.
- OMERS Administration Corp fully exited Brookfield Business Partners in Q1 2026, selling an estimated $424M.
- OMERS Administration Corp's ten largest holdings make up 35% of its $15.6B portfolio in Q1 2026.
- OMERS Administration Corp opened 175 new positions and closed 109 in Q1 2026.
- OMERS Administration Corp's portfolio value rose 11% quarter-over-quarter to $15.6B.
Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.